Navigation Links
Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection

MARKHAM, ON, June 28, 2007 /PRNewswire/ - Cytochroma Inc. announced today positive data from a Phase I clinical trial of CTA018 Injection. The initial top-line results from this trial showed that CTA018 was safe and well tolerated. Complete study results are expected in August 2007.

The recently completed Phase I trial was an open label, placebo-controlled, randomized study of CTA018 Injection administered to 20 healthy volunteers. In this trial, the safety of CTA018 Injection was evaluated after single doses of up to 180 mcg. Placebo and two strengths of CTA018, 90 mcg and 180 mcg, were subsequently studied during repeated dose administration. The trial was conducted at a single Canadian center. Key safety evaluations included adverse events, serum and urine calcium, serum ionized calcium and serum phosphorus. No drug-related adverse events were reported.

Significant reduction in the blood levels of parathyroid hormone (PTH) was observed in this trial, suggesting that CTA018 has potential as a treatment for secondary hyperparathyroidism in chronic kidney disease (CKD). Blood samples collected before and after repeated CTA018 administration documented a mean reduction in PTH level of more than 20% after five doses of 180 mcg.

"While this safety trial was not designed to demonstrate efficacy, we were pleasantly surprised to see a significant reduction of PTH levels after just a few doses of CTA018," stated Dr. Jukka Karjalainen, Executive Director, Product Development. "As expected, we did not see any elevations in serum or urine calcium or in serum phosphorus. Serum ionized calcium levels also remained unchanged. We believe that the PTH-lowering effect of CTA018 will be even more pronounced in CKD patients with secondary hyperparathyroidism."

About CTA018

CTA018 is the first compound in a new class of active Vitamin D analogs having a novel dual mechanism of action. CTA018 is
'"/>




Page: 1 2 3

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
8. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
9. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
10. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
11. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
Post Your Comments:
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... 2 data continue to show encouraging anti-tumor activity in,non- small cell ... ... XL647 administration, SAN FRANCISCO, Oct. 24 Exelixis, Inc.,(Nasdaq: ... study of XL647,an inhibitor of EGFR, HER2 and VEGFR kinases, in ...
... Clinical Studies TAX 323 and TAX 324 Published, ... that results of two clinical studies demonstrating that,Taxotere(R) ... fluorouracil for induction therapy, significantly improved overall,survival (OS) ... of,the head and neck (SCCHN) are published in ...
Cached Medicine Technology:Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference 2Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference 3Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference 4Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference 5Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 2Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 3Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 4Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 5Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 6Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 7
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on conservation ... today examining the current state of knowledge of the ... improved global surveillance strategies to combat the emergence of ... in West Africa that has claimed the lives of ... According to the World Health Organization (WHO), the ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
(Date:4/17/2014)... Council scientists and their partners have found that their ... the transmission of multiple sexually transmitted infections (STIs) in ... simplex virus 2 (HSV-2), and human papillomavirus (HPV). The ... gel is effective against multiple strains of HIV, and ... all three viruses of at least eight hours prior ...
(Date:4/17/2014)... WINSTON-SALEM, N.C. April 17, 2014 Meaningful ... from advanced cancer of the abdomen when treated ... HIPEC, according to a first-of-its-size analysis by physicians ... Forest Baptist has the largest reported, single-center experience ... Edward A. Levine, M.D., and analysis of 20 ...
(Date:4/17/2014)... D.C. -- The world is less than 40 years ... implications for people and governments, according to a top ... the first time in human history, food production will ... of land, water and energy," said Dr. Fred Davies, ... security. "Food issues could become as politically destabilizing by ...
Breaking Medicine News(10 mins):Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Food shortages could be most critical world issue by mid-century 2
... by the Dana-Farber Cancer Institute shows more than half ... developing treatment-related infertility problems.// ,Nearly 700 members ... were 40 years old or younger were surveyed. More ... they were concerned about being infertile as a result ...
... by nurses and dieticians have been found effective in ... shown they work only when these health professionals are ... at a program in which patients received their medications ... and dieticians on factors aimed at improving their cardiovascular ...
... therapeutic option for patients with complicated type 1 diabetes, ... // Now, a new study finds ... worse survival than patients on the transplant waiting list ... Association supports a pancreatic transplant for patients who have ...
... have identified a molecule that may help older people ... cells, called satellite cells, that line the outside of ... to form new muscle tissue. They also generate new ... cells respond when a certain protein called Notch is ...
... reports, patients who were treated for depression responded better ... in their blood.// ,An increasing amount of research ... depression, but the specifics have not been understood. Researchers ... vitamin B12 and the treatment of depression. ,The ...
... suggests a common antipsychotic drug might have caused a pulmonary ... pulmonary embolism results when a blood clot that developed elsewhere ... be deadly. Antipsychotic drugs have been linked to an increased ... shown an association between blood clots and the drug clozapine. ...
Cached Medicine News:Health News:Pancreas Transplant for Diabetics 2
... Exceptional comfort for those with ... Toric soft contact lenses let you enjoy ... other soft toric lensa difference youll especially ... throughout the day., This exceptional level of ...
Frequency 55 Toric monthly soft toric lenses....
Acuvue Toric is an exceptionally comfortable soft contact lens made especially for people with astigmatism. The Acuvue Toric lens is designed to comfortably fit the unique shape of your eye....
C 2.3K with lightweight headband: the practical alternative for spectacle-wearers. Delivered in protective designer case....
Medicine Products: